We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Manufacturers designing clinical trials for vertebral augmentation devices should pursue a randomized study with a follow-up period of at least two years, according to a new FDA guidance document.